|
|
2910 Seventh Street
Berkeley, CA 94710 USA
phone:(510) 204-7200
fax:
|
|
| Symbol |
XOMA |
| Exchange |
NASDAQ |
| Founded |
0 |
| Employees |
|
|
|
| www.xoma.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Antibody discovery and development |
|
| Management |
| Steven B. Engle, Chairman and Chief Executive Officer; William K. Bowes Jr., Chairman, Nominating & Governance Committee; Charles J. Fisher M.D., Director; Peter Barton Hutt, Director; Patrick J. Scannon M.D., Ph.D., Company Founder, Executive Vice President and Chief Medical Officer |
| |
|
|
|
|
|
|
|
| Keywords |
| antibody, therapeutics, disease mechanisms, biopharmaceutical, biotechnology |
|
|
|
|
|
|
| Description |
|
XOMA is at the forefront of antibody discovery and development, one of the most powerful and transformative fields of drug innovation today. Building on a pioneering proprietary pipeline, a world-class antibody discovery and development platform, plus multiple revenue streams, XOMA is creating innovative human antibody therapeutics with the potential to transform medicine and reshape people�s lives. Their cross functional teams use a battery of intellectual property and an integrated platform of antibody technologies and capabilities to engineer cutting-edge therapeutic antibodies. |
|
| Products / Services |
The Company's products are in various stages of development and all are subject to regulatory approval before it or its collaborators can commercially introduce any products.
|
|
| Technology / Differentiation |
| XOMA has proprietary technologies relating to recombinant antibodies and proteins, including bacterial cell expression systems and the Human Engineering method for creating human-like antibodies, both of which are available for licensing. The Company also uses these technologies in developing its own products. |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
